Save after changing Favorites. Use Share Link when you want the same list on another device.
Your link (Favorites):
All Favorites
#
Name
Description
Category
Type
Source
Website
TEN
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nilotinib, ATC L01EA03 (ausgeschlossen Nilotinib dispergiert in Apfelmus, es sei denn, der Hersteller genießt hierfür Patentschutz)
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJan 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-05
TEN
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Erythropoietin ausschließlich Epoetin alfa, (OBO) ATC B03XA01 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Telmisartan + Amlodipin, (OBG) ATC C09DB04 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ustekinumab, (OBG) ATC L04AC05 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Bempedoinsäure, (OBO) ATC C10AX15 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pegfilgrastim,(OBO) ATC L03AA13 für die Zeit 01.03.2025 - 28.02.2026 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Goserelin, ATC L02AE03
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJan 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-05
TEN
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Atovaquon, (OBG) ATC P01AX06 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Bempedoinsäure + Ezetimib, (OBO) ATC C10BA10 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Elbasvir + Grazoprevir, (OBO) ATC J05AP54 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Progesteron ausschließlich Darreichungsform VKA, (OBO) ATC G03DA04 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Clobazam, (OBG) ATC N05BA09 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Nitisinon, (OBO) ATC A16AX04 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Nebivolol, (OBG) ATC C07AB12 für die Zeit 01.03.2025 - 28.02.2027
Czechia – Lifts – DYNAMICKÝ NÁKUPNÍ SYSTÉM NA POŘÍZENÍ NOVÝCH VÝTAHŮ
ted.europa.eu
Buyer: Všeobecná fakultní nemocnice v Praze | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-01-06
TenderProcurement ContractCzechiaOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJan 6, 2027
Buyer: Všeobecná fakultní nemocnice v Praze | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-01-06
GRA
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
grants.gov
The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at ins...
GrantCash GrantUnited StatesOpen
AmountAward ceiling: $375,000
DeadlineJan 7, 2027
The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole.This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the partici...
GRA
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
grants.gov
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJan 7, 2027
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within.
GRA
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
grants.gov
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and...
GrantCash GrantUnited StatesOpen
AmountAward ceiling: $500,000
DeadlineJan 7, 2027
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.
GRA
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
grants.gov
This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relations...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJan 7, 2027
This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control.
GRA
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
grants.gov
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clin...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJan 7, 2027
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevent...
No saved opportunities on this page
Use the star icon near an opportunity title to add it to Favorites.
📅 Best viewed on desktop - or rotate your phone to landscape mode.
#
Opportunity
Type
Region / Country
Amount
Deadline
Source
39276
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nilotinib, ATC L01EA03 (ausgeschlossen Nilotinib dispergiert in Apfelmus, es sei denn, der Hersteller genießt hierfür Patentschutz)Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-01-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Buyer: Všeobecná fakultní nemocnice v Praze | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-01-06
39296
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale re...
The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole.This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For the purpose of this NOFO, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.
39297
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within.
39298
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scienti...
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.
39299
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awaren...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control.
39300
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investi...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.
No saved opportunities on this page. Use the star icon near an opportunity title.
